Julia Glade Bender

TL;DR: Germline testing should be considered for all children with cancer, and clinical actionability additionally included screening, risk reduction in relatives, reproductive use, and use of targeted therapies.

TL;DR: Existing literature supports the prognostic significance of NS in pediatric solid tumor patients and underscores the need for prospective studies to better elucidate underlying physiological changes in this population.

TL;DR: In summary, this article reviews the current evidence for targeting childhood cancers with GPC3-directed immunotherapies and considers a key pediatric-specific consideration of G PC3-targeted immunotherapeutics which can be physiologically expressed in normal tissues during the first year of life, particularly in the liver and kidney.

TL;DR: No pediatric studies to date have prospectively evaluated prognosis communication or influences on decision making in poor‐prognosis childhood cancer.

TL;DR: The RET gene can be oncogenically activated by point mutations, in-frame deletions, and chromosomal rearrangements, gain-of-function events that render the RET tyrosine kinase constitutively active, leading to the hereditary autosomal-dominant cancer syndrome called multiple endocrine neoplasia type 2 (MEN2).